D 2004

Methylation of histone H3K9 in human blood cells and in granulocytes of patients with myeloid leukemia

LUKÁŠOVÁ, Emilie, Martin FALK, Zdeněk KOŘISTEK, Stanislav KOZUBEK, Sergei GRIGORYEV et. al.

Basic information

Original name

Methylation of histone H3K9 in human blood cells and in granulocytes of patients with myeloid leukemia

Name in Czech

Metylace histonu H3K9 v lidských krevních buňkách a v granulocytech pacientů s myeloidní leukémií

Authors

LUKÁŠOVÁ, Emilie (203 Czech Republic), Martin FALK (203 Czech Republic), Zdeněk KOŘISTEK (203 Czech Republic), Stanislav KOZUBEK (203 Czech Republic, guarantor), Sergei GRIGORYEV (840 United States of America), Michal KOZUBEK (203 Czech Republic), Vladan ONDŘEJ (203 Czech Republic) and Iva KROUPOVÁ (203 Czech Republic)

Edition

First Edition 2004. Brno, Biophysics of the Genome, p. 53-57, 5 pp. 2004

Publisher

Masaryk University

Other information

Language

English

Type of outcome

Stať ve sborníku

Field of Study

Genetics and molecular biology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14330/04:00009703

Organization unit

Faculty of Informatics

ISBN

80-210-3560-9

Keywords in English

cytometry

Tags

Tags

International impact
Změněno: 29/10/2010 14:32, prof. RNDr. Michal Kozubek, Ph.D.

Abstract

ORIG CZ

V originále

We show that common heterochromatin antigenic protein markers (HP1alpha, beta, gamma, mono-, di-, and tri-methylated histone H3K9), while present in human blood progenitor CD34+ cells, differentiated lymphocytes and monocytes, are absent in neutrophile granulocytes and, to large extent, in eosinophiles. Mono-methylated and, in particular, di-methylated H3K9 are present to variable degrees in the granulocytes of CML patients, without being accompanied by HP1 proteins. In patients with an acute phase of CML and in AML patients, strong methylation of H3K9 and all isoformes of HP1 are detected. In chronic forms of CML, no strong correlations among the level of histone methylation, disease progression and modality of treatment were observed. Histone methylation was found even in cured patients without BCR/ABL translocation, suggesting an incomplete process of developmentally-regulated chromatin remodeling in the granulocytes of these patients. Similarly, reprogramming of leukemia HL-60 cells to terminal differentiation by retinoic acid does not eliminate H3K9 methylation and the presence of HP1 isoformes from differentiated granulocytes. Thus our study shows for the first time that histone H3 methylation may be dramatically changed during normal cell differentiation. The residual histone H3 methylation in myeloid leukemia cells suggests an incomplete chromatin condensation that may be linked to the leukemia cell proliferation and may be important for the prognosis of disease treatment and relapse.

In Czech

Metylace histonu H3K9 v lidských krevních buňkách a v granulocytech pacientů s myeloidní leukémií.

Links

AV0Z5004920, plan (intention)
Name: Biofyzikální vlastnosti živých systémů a jejich změny vlivem faktorů vnějšího prostředí
GA202/02/0804, research and development project
Name: Určení radiačního rizika pro vznik chronické myeloidní leukémie na základě měření vzdáleností mezi geny ABL a BCR v hematopoietických buňkách
Investor: Czech Science Foundation, Chronic myeloid leukemia radiation risk estimation based on BCR-ABL distances in hemotopoietic cells
IAA1065203, research and development project
Name: Využití kombinace laserových mikrosvazkových a cytometrických technik ke studiu struktury a dynamiky lidského genomu
Investor: Academy of Sciences of the Czech Republic, The use of combination of laser microbeam and cytometric techniques in the study of the structure and dynamics of human genome
KSK5052113, research and development project
Name: Struktura, exprese a interakce genomu
ME 565, research and development project
Name: Struktura a funkce interfázních chromosomů
NC6987, research and development project
Name: Epigeneticky kontrolované změny exprese genů u nádorových onemocnění
Investor: Ministry of Health of the CR, Epigenetic control of gene expression in malignant diseases